*Important*
The NENC ICB Respiratory Network recommends that all inhalers should be prescribed by brand for patient safety, to ensure that the correct device is dispensed to support correct technique and avoid patient confusion and medication errors.
Choice of inhaler device should be based on patient ability to use. Devices should be chosen based on availability for the type of drug to be prescribed and the patient’s ability to use it.
Refer to local guidelines for information on preferred options.
Note: All new patients should be started on the updated formulary choices as per local/national guidelines.
When inhalers are removed from the formulary, existing, stable, patients should continue to receive the non-formulary device. Treatment should not be changed unless a full face to face review has been conducted.
Benralizumab Fasenra® |
Formulary
|
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
|
Dupilumab Dupixent® |
Formulary
|
|
MHRA Drug Safety Update Nov 2022: Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management NICE TA751: Dupilumab for treating severe asthma with type 2 inflammation |
|
Mepolizumab Nucala® |
Formulary
|
|
NICE TA671: Mepolizumab for treating severe eosinophilic asthma |
|
Omalizumab Xolair® |
Formulary
|
|
NICE TA278: Omalizumab for treating allergic asthma NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria NICE TA678: Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal) |
|
Reslizumab Cinquil® |
Formulary
|
|
NICE TA479 Reslizumab for treating severe eosinophilic asthma |
|
Tezepelumab Tezspire® |
Formulary
|
|
NICE TA880: Tezepelumab for treating severe asthma |
|